Semaglutide
ApprovedA long-acting GLP-1 receptor agonist approved for type 2 diabetes and for weight management, dosed once weekly.
Weight loss
Guide
Titrating a dose: why you climb, and how to know when to stop
Every approved incretin protocol climbs in steps instead of starting at the target dose. Here is the reasoning behind that, and the one mistake that breaks a schedule.
Titration means raising a dose in planned steps, so that if something goes wrong it goes wrong at a dose you can still retreat from. For the compounds where it is standard practice, the side effects track the dose and they subside with continued exposure. Climb slowly enough and you end up tolerating a dose that would have floored you on day one.
What follows is the shape of a titration and where people go wrong with it. It does not tell you what dose to take. The schedules on our compound pages report what sources say, not what we advise.
Why climbing works
Nausea, vomiting and constipation are what limit the incretin agonists in practice. Both facts about them matter. They get worse as the dose goes up, and they get better the longer you sit at one. Put those together and the argument writes itself: hold where you are until your body has caught up, and the next step starts from firmer ground.
So the interval between steps is doing the work, not the size of the step. Doubling after four uneventful weeks is a gentler thing to do than a tenth of that increase on day three.
The steps
Start below where you intend to end
In most trial protocols the starting dose is a small fraction of the target and nobody expects it to do much. It is a probe. It exists to find out how you respond.
Hold each step until it is uneventful
"Four weeks per step" is a minimum, not an appointment. If week four is still rough, the answer is a fifth week at the same dose.
Change one thing at a time
Raise two compounds in the same week and a bad reaction tells you nothing. You will not know which one to pull back.
Know that going back is available
Stepping down is a normal move and not a failure. It is only available if the steps were small enough to leave you somewhere to return to.
Log the step and the date
A titration is a protocol that changes under you. Without a record of what you were taking in which week, nothing that happened can be interpreted afterwards. The tracker stores a dose ladder for this.
Where titrations go wrong
Climbing on the calendar, not the response
The most common failure by a distance. The schedule sets a minimum interval. Your body sets the real one.
Starting at the dose you read about
The number in the headline is usually the maintenance dose, arrived at after months of climbing.
Raising two compounds at once
Halves what you learn and takes away any precise way to correct it.
Holding a step longer than planned
Costs you time and nothing else. Time is the cheapest thing you are spending here.
Stepping back down after a bad week
This is the move the entire approach exists to keep available.
Where this comes up
Tirzepatide
ApprovedA once-weekly dual agonist that activates both the GIP and GLP-1 receptors, approved for type 2 diabetes and for weight management.
Weight loss
Retatrutide
Early human trialsAn investigational once-weekly triple agonist acting on the GLP-1, GIP and glucagon receptors. Not approved anywhere.
Weight loss
Survodutide
Clinical trialsA GLP-1 and glucagon dual agonist in phase 3, and one of the more advanced candidates for fatty liver disease rather than weight alone.
Weight loss
Related guides
This page is educational. It describes what published research reports, not what you should do. Peptides discussed here are largely not approved for human use, and nothing on Bioalmanac is medical advice.
Last updated 21 Aug 2026
Terms used here
- Titration
- Raising a dose in planned steps rather than starting at the target, so side effects appear at a dose small enough to retreat from.
- GLP-1 agonist
- A drug acting on the receptor for glucagon-like peptide-1, a gut hormone that signals fullness and slows stomach emptying.